Le Lézard
Classified in: Science and technology, Business
Subjects: AWD, TDS

Klear.ai Named as a RMIS Report Innovator Continuing Outstanding Performance in the RMIS and Claims Market


CYPRESS, Calif., May 8, 2024 /PRNewswire/ -- Klear.ai, a leader in risk, claims, and analytics solutions, proudly announces its continued high ranking in the 2024 RMIS Report ? for the second year in a row! Highlighting their continued innovation and leadership in the sector through significant technological advancements and customer-focused developments.

"Our recent advancements in GenAI and industry recognition underscore Klear.ai's commitment to providing practical and leading technology in risk and claims management," stated Brijesh Kumar, CEO of Klear.ai. "This dedication to innovation, combined with our comprehensive approach to industry challenges, is part of our customer-first approach, ensuring that every solution improves our clients' ability to manage risks effectively and efficiently."

The Klear.ai Platform continues to garner recognition, and awards for its technological advancements.

Klear.ai was also awarded the "Most Innovative Claims & Risk Management Software Firm 2024 ? USA" by AI Magazine and. and "Top 10 Audit Management Solution Providers 2023" by GRC Outlook Magazine, highlighting our innovative approach to audit management solutions. These accolades reflect an unwavering commitment to innovation in risk and claims management software.

As an industry pioneer and partner to notable private and public sector early adopters, Klear.ai leveraged native AI technology to enhance platform functionality and user adaptability, distinguishing itself by providing risk and claims professionals with tools that support more resilient and efficient operational frameworks.

Further advancements in safety and fraud detection analytics have significantly bolstered our risk management capabilities. The platform now includes a comprehensive risk scoring and text mining glossary, enhancing data intelligence. Additionally, we've rolled out AI improvements that streamline user interactions, including conversational queries and automated task handling, complemented by a seamless Microsoft Teams integration to foster effective team collaboration.

Celebrating Success at RISKWORLD 2024

Join us at Booth #309 at RISKWORLD 2024 to explore the future of insurance analytics and claims management. For partnership discussions or deeper insights, please schedule a meeting or visit us directly at the event.

For more details about Klear.ai's innovative solutions, visit our website at https://www.klearai.com.

Press & Media Contact [Klear.ai]:
Shivanshu Bansal
Phone: +1 (925) 640-7156
Email: [email protected]
Website: https://www.klearai.com
LinkedIn: Follow Klear.ai on LinkedIn
YouTube: Watch on YouTube

SOURCE Klear.ai


These press releases may also interest you

at 20:14
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 20:00
SUNRATE joins Mastercard's Priceless Planet Coalition
SUNRATE, an intelligent global payment and treasury management platform today announced it has joined Mastercard Priceless Planet Coalition in support of fighting climate change through funding the restoration of 100 million trees. This announcement...

at 20:00
E&R Engineering Corp. Unveils Cutting-Edge Solutions at Semicon SEA 2024 in Kuala Lumpur
The advanced laser and plasma solution provider from Taiwan, E&R Engineering Corp., is confirmed to attend the feast in Semiconductor industry, Semicon SEA 2024, held in Kuala Lumpur, Malaysia. With the 30-year dedication in the semiconductor...

at 17:20
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines' ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

More news about Science and technology...


News published on and distributed by: